ACADIA Pharmaceuticals

ACAD

1 Obserwujący

$17.44

+3.01%

$0.51

Obserwuj

5 Sierpień

Upcoming Earnings

Market Cap.

P/E

Overview Metrics Financials

ACAD Fair Price

$12.70

Undervalued by 40.5%

Aby wyświetlić sprawiedliwą cenę akcji, musisz być członkiem Bulios Black.

My Notes

Začít psát

Profile

ACADIA Pharmaceuticals Inc. (ACAD) is an American biopharmaceutical company focusing on the development of innovative drugs for the treatment of central nervous system disorders. Their main product, pimavanserin, is an approved medication for the treatment of hallucinations and delusions associated with Parkinson's disease. ACADIA Pharmaceuticals actively engages in clinical trials and research to discover new therapeutic options for patients suffering from neurological disorders. ACADIA Pharmaceuticals Inc. (ACAD) shares could be suitable for investors looking to invest in the biopharmaceutical sector with a focus on innovative treatment approaches for neurological conditions.

Feed

There are no posts to show right now.